{"title":"胃癌辅助化疗的最佳时间:越短越好吗?","authors":"Hye Sook Han","doi":"10.5230/jgc.2022.22.e13","DOIUrl":null,"url":null,"abstract":"https://jgc-online.org Several large-randomized trials have indicated that adjuvant chemotherapy after curative resection with D2 lymph node dissection has a significant survival benefit in Asian patients with resectable gastric cancer. Adjuvant chemotherapy in Asian patients with resectable gastric cancer is primarily supported by the results of 2 large, randomized phase 3 trials: the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) and the Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC) [1,2]. Based on the results of these trials, both chemotherapy regimens (S-1 for 1 year or capecitabine plus oxaliplatin for 6 months) are currently accepted in East Asia as standard adjuvant chemotherapy regimens for pathological stage II or III gastric cancer after D2 gastrectomy [3,4]. However, as S-1 monotherapy has limited survival benefits in patients with stage III gastric cancer, oral fluoropyrimidine-based doublet regimens (capecitabine plus oxaliplatin [XELOX], S-1 plus oxaliplatin [SOX], or S-1 plus docetaxel) are recommended as adjuvant chemotherapy for these patients [2-6] (Fig. 1A).","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?\",\"authors\":\"Hye Sook Han\",\"doi\":\"10.5230/jgc.2022.22.e13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"https://jgc-online.org Several large-randomized trials have indicated that adjuvant chemotherapy after curative resection with D2 lymph node dissection has a significant survival benefit in Asian patients with resectable gastric cancer. Adjuvant chemotherapy in Asian patients with resectable gastric cancer is primarily supported by the results of 2 large, randomized phase 3 trials: the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) and the Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC) [1,2]. Based on the results of these trials, both chemotherapy regimens (S-1 for 1 year or capecitabine plus oxaliplatin for 6 months) are currently accepted in East Asia as standard adjuvant chemotherapy regimens for pathological stage II or III gastric cancer after D2 gastrectomy [3,4]. However, as S-1 monotherapy has limited survival benefits in patients with stage III gastric cancer, oral fluoropyrimidine-based doublet regimens (capecitabine plus oxaliplatin [XELOX], S-1 plus oxaliplatin [SOX], or S-1 plus docetaxel) are recommended as adjuvant chemotherapy for these patients [2-6] (Fig. 1A).\",\"PeriodicalId\":56072,\"journal\":{\"name\":\"Journal of Gastric Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastric Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5230/jgc.2022.22.e13\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastric Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5230/jgc.2022.22.e13","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?
https://jgc-online.org Several large-randomized trials have indicated that adjuvant chemotherapy after curative resection with D2 lymph node dissection has a significant survival benefit in Asian patients with resectable gastric cancer. Adjuvant chemotherapy in Asian patients with resectable gastric cancer is primarily supported by the results of 2 large, randomized phase 3 trials: the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) and the Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC) [1,2]. Based on the results of these trials, both chemotherapy regimens (S-1 for 1 year or capecitabine plus oxaliplatin for 6 months) are currently accepted in East Asia as standard adjuvant chemotherapy regimens for pathological stage II or III gastric cancer after D2 gastrectomy [3,4]. However, as S-1 monotherapy has limited survival benefits in patients with stage III gastric cancer, oral fluoropyrimidine-based doublet regimens (capecitabine plus oxaliplatin [XELOX], S-1 plus oxaliplatin [SOX], or S-1 plus docetaxel) are recommended as adjuvant chemotherapy for these patients [2-6] (Fig. 1A).
期刊介绍：
The Journal of Gastric Cancer (J Gastric Cancer) is an international peer-reviewed journal. Each issue carries high quality clinical and translational researches on gastric neoplasms. Editorial Board of J Gastric Cancer publishes original articles on pathophysiology, molecular oncology, diagnosis, treatment, and prevention of gastric cancer as well as articles on dietary control and improving the quality of life for gastric cancer patients. J Gastric Cancer includes case reports, review articles, how I do it articles, editorials, and letters to the editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
